本文選題：上市醫(yī)藥企業(yè)　切入點(diǎn)：知識(shí)產(chǎn)權(quán)管理　出處：《遼寧大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：知識(shí)經(jīng)濟(jì)日益發(fā)展,知識(shí)產(chǎn)權(quán)已經(jīng)成為經(jīng)濟(jì)全球化大背景下企業(yè)競(jìng)爭(zhēng)的關(guān)鍵所在。各大企業(yè)為了更好地融入到全球化中,提高企業(yè)的核心競(jìng)爭(zhēng)力以應(yīng)對(duì)激烈的市場(chǎng)競(jìng)爭(zhēng),提高企業(yè)自身的知識(shí)產(chǎn)權(quán)管理水平已成為當(dāng)務(wù)之急。本文基于我國(guó)醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)的具體特征,結(jié)合相關(guān)理論研究,一方面,有針對(duì)性地把握知識(shí)產(chǎn)權(quán)、知識(shí)產(chǎn)權(quán)管理以及醫(yī)藥企業(yè)這三者之間的關(guān)系;另一方面,從知識(shí)產(chǎn)權(quán)管理全過(guò)程的視角出發(fā),建立了針對(duì)我國(guó)醫(yī)藥企業(yè)的知識(shí)產(chǎn)權(quán)管理績(jī)效評(píng)價(jià)指標(biāo)體系;在此基礎(chǔ)上,采用模糊綜合評(píng)價(jià)法構(gòu)建模型。更進(jìn)一步選取我國(guó)上市醫(yī)藥樣本企業(yè)進(jìn)行實(shí)證評(píng)價(jià)。本文旨在對(duì)我國(guó)醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理績(jī)效的評(píng)價(jià)提供科學(xué)可操作的方法,并對(duì)完善我國(guó)醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理工作提出合理的意見(jiàn)和建議,以期促進(jìn)我國(guó)醫(yī)藥企業(yè)的可持續(xù)發(fā)展。(1)本文在對(duì)知識(shí)產(chǎn)權(quán)、企業(yè)知識(shí)產(chǎn)權(quán)管理、績(jī)效評(píng)價(jià)相關(guān)理論及醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理特征等進(jìn)行分析的基礎(chǔ)上,結(jié)合已有研究和我國(guó)醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理具體實(shí)踐,認(rèn)為對(duì)醫(yī)藥企業(yè)的知識(shí)產(chǎn)權(quán)管理存在顯著影響的有五個(gè)方面,分別為:知識(shí)產(chǎn)權(quán)管理平臺(tái)建設(shè)、知識(shí)產(chǎn)權(quán)研發(fā)與運(yùn)用、知識(shí)產(chǎn)權(quán)保護(hù)、知識(shí)產(chǎn)權(quán)經(jīng)營(yíng)及知識(shí)產(chǎn)權(quán)戰(zhàn)略。在此基礎(chǔ)上,構(gòu)建了針對(duì)我國(guó)醫(yī)藥企業(yè)的知識(shí)產(chǎn)權(quán)管理績(jī)效評(píng)價(jià)指標(biāo)體系。進(jìn)一步根據(jù)研究需要,本文選取了模糊綜合評(píng)價(jià)法作為具體的評(píng)價(jià)方法,也在此基礎(chǔ)上建立了醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理績(jī)效的評(píng)價(jià)模型。(2)選取醫(yī)藥行業(yè)中具有較高競(jìng)爭(zhēng)力的健康元藥業(yè)集團(tuán)股份有限公司,運(yùn)用本文構(gòu)建的醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理績(jī)效評(píng)價(jià)模型進(jìn)行實(shí)證評(píng)價(jià)研究。通過(guò)研究得出,即便是對(duì)于在醫(yī)藥行業(yè)百?gòu)?qiáng)榜上名列前茅的上市企業(yè),其全過(guò)程的知識(shí)產(chǎn)權(quán)管理績(jī)效也只是處于一般水平,只在知識(shí)產(chǎn)權(quán)管理的部分過(guò)程處于“較好”等級(jí),而總體水平卻差強(qiáng)人意。這說(shuō)明我國(guó)醫(yī)藥企業(yè)對(duì)知識(shí)產(chǎn)權(quán)的管理有待加強(qiáng),需要進(jìn)一步改善醫(yī)藥企業(yè)的知識(shí)產(chǎn)權(quán)管理工作。
[Abstract]:With the development of knowledge economy, intellectual property has become the key of enterprise competition under the background of economic globalization. In order to better integrate into the globalization, improve the core competitiveness of enterprises to cope with the fierce market competition. It has become an urgent task to improve the intellectual property management level of enterprises. Based on the specific characteristics of intellectual property rights of pharmaceutical enterprises in China, this paper combines relevant theoretical research, on the one hand, to grasp intellectual property rights in a targeted manner. The relationship between intellectual property management and pharmaceutical enterprises; on the other hand, from the perspective of the whole process of intellectual property management, the performance evaluation index system of intellectual property management for pharmaceutical enterprises in China is established. The fuzzy comprehensive evaluation method is used to construct the model. Furthermore, the listed pharmaceutical sample enterprises in China are selected for empirical evaluation. The purpose of this paper is to provide a scientific and operable method for evaluating the intellectual property management performance of Chinese pharmaceutical enterprises. In order to promote the sustainable development of pharmaceutical enterprises in China, the author puts forward some reasonable opinions and suggestions to improve the intellectual property management of pharmaceutical enterprises in China. Based on the analysis of the relevant theories of performance evaluation and the characteristics of intellectual property management of pharmaceutical enterprises, combined with the existing research and the specific practice of intellectual property management of pharmaceutical enterprises in China, It is concluded that there are five aspects that have significant influence on the intellectual property management of pharmaceutical enterprises, namely, the construction of intellectual property management platform, the development and application of intellectual property rights, and the protection of intellectual property rights. The intellectual property management and intellectual property strategy. On this basis, the performance evaluation index system of intellectual property management for pharmaceutical enterprises in China is constructed. In this paper, the fuzzy comprehensive evaluation method is selected as the concrete evaluation method. On this basis, the evaluation model of intellectual property management performance of pharmaceutical enterprises is established. Using the intellectual property management performance evaluation model of pharmaceutical enterprises constructed in this paper to carry out empirical evaluation research. Through the research, it is concluded that, even for the top 100 listed companies in the pharmaceutical industry, The whole process of intellectual property management performance is only in the general level, only in part of the process of intellectual property management in the "better" level, However, the overall level is not satisfactory, which indicates that the management of intellectual property in Chinese pharmaceutical enterprises needs to be strengthened, and the management of intellectual property rights in pharmaceutical enterprises should be further improved.
【學(xué)位授予單位】：遼寧大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F426.72;F273.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 賀巧玲;;中國(guó)醫(yī)藥產(chǎn)業(yè)結(jié)構(gòu)與知識(shí)產(chǎn)權(quán)保護(hù)[J];科技與法律;2016年02期

2 陳俊霖;宋硯秋;王云亭;張笑語(yǔ);王志鋒;;知識(shí)產(chǎn)權(quán)管理績(jī)效評(píng)價(jià):一種基于專家意見(jiàn)遴選的模糊綜合評(píng)判模型[J];中國(guó)科技資源導(dǎo)刊;2014年06期

3 顧曉燕;;自主創(chuàng)新模式對(duì)高技術(shù)產(chǎn)業(yè)知識(shí)產(chǎn)權(quán)創(chuàng)造影響的實(shí)證研究[J];軟科學(xué);2014年01期

4 李潭;陳偉;;基于灰類白化模型的知識(shí)產(chǎn)權(quán)管理績(jī)效評(píng)價(jià)[J];統(tǒng)計(jì)與決策;2013年19期

5 劉海波;李黎明;;面向“創(chuàng)新2020”的知識(shí)產(chǎn)權(quán)戰(zhàn)略布局的分析與建議[J];中國(guó)科學(xué)院院刊;2013年04期

6 郭亞星;;論醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)戰(zhàn)略[J];中國(guó)西部科技;2013年06期

7 趙嘉茜;宋偉;葉胡;;高技術(shù)產(chǎn)業(yè)知識(shí)產(chǎn)權(quán)運(yùn)營(yíng)績(jī)效研究[J];中國(guó)高校科技;2013年Z1期

8 顧曉燕;;中國(guó)高技術(shù)產(chǎn)業(yè)知識(shí)產(chǎn)權(quán)創(chuàng)造影響因素的實(shí)證檢驗(yàn)[J];經(jīng)濟(jì)學(xué)家;2012年11期

9 馮楚建;唐恒;付麗穎;;醫(yī)藥企業(yè)知識(shí)產(chǎn)權(quán)管理與績(jī)效分析——基于國(guó)家高新技術(shù)開發(fā)區(qū)的調(diào)查[J];科技進(jìn)步與對(duì)策;2012年03期

10 陳偉;康鑫;馮志軍;田世海;;基于群組決策特征根法的高技術(shù)企業(yè)知識(shí)產(chǎn)權(quán)開發(fā)評(píng)價(jià)指標(biāo)識(shí)別[J];科技進(jìn)步與對(duì)策;2011年11期

相關(guān)碩士學(xué)位論文 前3條

1 朱春華;基于提升企業(yè)競(jìng)爭(zhēng)優(yōu)勢(shì)的知識(shí)產(chǎn)權(quán)管理研究[D];江蘇大學(xué);2010年

2 張夏莉;中國(guó)高新技術(shù)企業(yè)跨國(guó)經(jīng)營(yíng)中知識(shí)產(chǎn)權(quán)管理體系構(gòu)建[D];哈爾濱工程大學(xué);2009年

3 張序晶;企業(yè)利用知識(shí)產(chǎn)權(quán)獲得競(jìng)爭(zhēng)優(yōu)勢(shì)研究[D];東北大學(xué);2005年

，

本文編號(hào)：1583163